L-Arginine, L-α-glutamyl-L-α-aspartyl-:Exports & Compliance White Paper 2026

I. Executive Summary

CAS 175175-23-2, named systematically as L-arginine, L-alpha-glutamyl-L-alpha-aspartyl-, is the tripeptide Glu-Asp-Arg, sometimes abbreviated EDR. It sits in the large commercial category of short synthetic peptides used as research materials and as functional cosmetic ingredients. Two facts define how it must be bought and sold. First, it has no approved therapeutic indication in any jurisdiction, and material supplied for research purposes is Research Use Only material, not for human or veterinary use and not a finished consumer or medicinal product. Second, where it is supplied as a cosmetic ingredient, the regulatory obligations attach to the finished product and to the responsible person, not to the peptide manufacturer, yet the ingredient supplier must still provide the safety, traceability and quality documentation that makes that downstream compliance possible.

Chemically the molecule is deceptively simple. Three residues, a molecular mass in the low hundreds of daltons and a net negative charge at neutral pH make it easy to synthesise and easy to characterise, but both terminal positions carry specific degradation risks: N-terminal glutamic acid cyclises to pyroglutamate, and the aspartic acid residue can form aspartimide and subsequently isoaspartate. Buyers should require identity by accurate mass, a stability-indicating method that resolves these species, assigned peptide content, counter-ion and residual-solvent data, water content, and a documented related-substance profile.

The sections below cover the physicochemical profile and degradation chemistry specific to EDR, the route-class synthesis and purification options used by peptide CDMOs, the analytical and quality-system expectations for research-grade and cosmetic-grade campaigns, the European, United States and Chinese cosmetic and chemical regulatory framework, ESG and traceability obligations including halal, kosher, vegan and ISO 16128 documentation, and the cold-chain and packaging controls that preserve material integrity. Regional coverage addresses the Chinese, Indian and European ecosystems. No skin, anti-ageing or health claim is made for this material anywhere in this paper.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Glu-Asp-Arg combines two acidic side chains with one guanidinium group, giving a strongly hydrophilic, permanently charged tripeptide whose behaviour in solution is dominated by carboxylate chemistry and by salt formation with the arginine function. Its polarity makes it straightforward to handle in aqueous systems and difficult to retain by conventional reversed-phase chromatography unless ion-pairing or hydrophilic interaction conditions are used. Because no aromatic residue is present, there is no intrinsic ultraviolet chromophore beyond the peptide bond, so detection is commonly performed at low wavelength or by mass spectrometry.

• Mass, Charge and Solubility Profile: The three residues give a molecular mass of approximately 418 Da for the free peptide, with the counter-ion load reported separately; two carboxylate side chains against one guanidinium and one ammonium group give a net negative charge at neutral pH and an acidic theoretical isoelectric point, producing high aqueous solubility and low retention in reversed-phase systems.
• Terminal and Side-Chain Degradation Pathways: N-terminal glutamic acid cyclises to pyroglutamate, particularly under acidic conditions and on storage, while the aspartic acid residue can form an aspartimide intermediate that hydrolyses to isoaspartate; both products are close in mass or isobaric to the parent and must be resolved chromatographically rather than assumed absent.

2.2 Synthesis and Manufacturing Technologies

Production follows the standard route classes of the peptide industry: stepwise solid-phase assembly with fluorenylmethoxycarbonyl protection on a polymeric support, or solution-phase fragment coupling, which for a tripeptide is often the more economical choice at scale because the number of isolations is small and intermediates can be crystallised. Reputable suppliers describe capability at route-class level and protect reagent, resin and cycle detail under confidentiality agreements. The differentiating decisions are how side-chain protection of the two carboxylates is handled, how the cyclisation-prone N-terminus is managed, and how the counter-ion is set at the end.

• Assembly Strategy and Side-Chain Protection: Protected glutamate and aspartate residues with orthogonal ester protection are used to prevent side-chain branching and aspartimide formation during coupling and deprotection, with coupling completion monitored in process and, in solution-phase routes, with isolation and control of each intermediate.
• Purification, Counter-Ion Control and Lyophilisation: Preparative reversed-phase or ion-exchange chromatography with pooling against analytical release criteria, followed by deliberate salt-form selection, desalting, concentration and lyophilisation under a cycle designed to give a stable, low-moisture cake with a defined residual solvent profile.

2.3 Core Application Matrix

• Laboratory and Assay Research: Supply of characterised material to academic, biotechnology and contract laboratories running biochemical, receptor-binding or cell-based assays, where identity, peptide content and counter-ion consistency determine reproducibility.
• Cosmetic Ingredient Supply: Delivery to cosmetic manufacturers and ingredient formulators as a functional tripeptide raw material, supported by the safety, impurity, traceability and quality documentation that a responsible person needs for finished-product compliance.
• Analytical Reference and Method Development: Use as a characterised material for HPLC, LC-MS and amino-acid analysis method development, system suitability and forced-degradation work mapping pyroglutamate and isoaspartate formation.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand divides into two streams that behave very differently. Research demand is lumpy, project-driven and specification-heavy, driven by funding cycles and by the analytical packages buyers now routinely require. Cosmetic ingredient demand is steadier, volume-driven and documentation-heavy, driven by brand formulation pipelines and by the increasing documentation burden that modern cosmetics regulation places on ingredient suppliers. Both streams have moved away from catalogue buying toward qualified-supplier relationships with change-control undertakings.

3.2 Capacity Distribution and Export Flows

Synthesis capacity for short peptides is concentrated in China and India, where protected amino acids, resins and preparative purification throughput are most competitive, with European and North American capacity concentrated in regulated, cosmetic-grade and reference-grade campaigns where documentation and auditability matter more than unit cost. Tripeptides are straightforward to make, so capacity is rarely the constraint; availability of validated methods, of amino-acid analysis and high-resolution mass spectrometry, and of qualified cold-chain logistics is what separates suppliers. Export flows move from Asian synthesis sites to Western and regional distribution hubs.

3.3 Market Bifurcation and Pricing Dynamics

Three price tiers are visible. Catalogue material with a minimal certificate competes on price and frequently carries an undefined counter-ion load and unassigned peptide content. Certified research material adds accurate-mass identity, assigned content, residual solvent and water data and a related-substance profile. Cosmetic-grade material adds a further layer: heavy metals, endotoxin or bioburden limits, ISO 22716-aligned manufacturing, allergen and animal-origin statements, and halal, kosher and vegan certification where brands require it. Because salt and water burden can move the effective peptide delivered by a fifth or more, quotations omitting content and counter-ion data should be treated as incomplete regardless of headline price.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance obligations for this tripeptide differ according to declared end use, which is precisely why an end-use declaration must be obtained before shipment. Material declared for research is governed by chemical and research-use rules. Material declared as a cosmetic ingredient is governed by cosmetics legislation in the destination market, and material presented for human administration would be an unlicensed medicinal product. The instruments below are those a competent supplier should be able to evidence.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• EU Cosmetics Regulation 1223/2009: Where the material is supplied as a cosmetic ingredient, the finished product placed on the EU market requires a responsible person, a product information file, a safety assessment by a qualified safety assessor, notification through the cosmetic product notification portal, and ingredient labelling under the international nomenclature of cosmetic ingredients, with the ingredient supplier providing the supporting safety and impurity data.
• REACH, CLP and Research-Use Classification: Chemical supply requires a defensible REACH position, compliant safety data sheet and CLP-aligned labelling, and where the material is declared for scientific research and development the exemption basis must be documented rather than assumed, with candidate-list and restriction screening recorded before export.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• MoCRA Facility and Product Listing: Under the Modernization of Cosmetics Regulation Act, cosmetic ingredient supply supports a downstream obligation for facility registration and product listing, for a responsible person, for safety substantiation and for serious adverse event reporting; the ingredient supplier should be able to provide the technical dossier material that makes those obligations achievable.
• TSCA Inventory and Unapproved Drug Position: Import into the United States requires a confirmed TSCA inventory or exemption position and correct certification at entry, and material promoted for human administration would be an unapproved and misbranded new drug, a positioning that no legitimate supplier should adopt.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Even a three-residue peptide consumes multiples of its own mass in process solvent, and cosmetic-sector buyers in particular now apply supply-chain environmental and ethical criteria to ingredient suppliers. Solvent selection and recovery, fluorinated reagent use at cleavage, and the energy intensity of purification and lyophilisation are the recurring audit topics.

5.1 Carbon Footprint and Circular Economy

The dominant contributors are aprotic polar solvents used in coupling and washing, acetonitrile or alcohol modifiers used in preparative chromatography, and electricity for freeze-drying and refrigerated storage. Practical mitigations include solvent recovery by distillation, substitution toward greener coupling media, pooling strategies that reduce chromatographic runs, and heat recovery on lyophiliser condensers. Suppliers able to report solvent intensity per kilogram released and to evidence a Scope 1 and Scope 2 inventory under ISO 14001 are increasingly preferred in brand and pharmaceutical tenders.

5.2 Sustainable Sourcing and Traceability

Cosmetic and research buyers both require documented origin of protected amino acids and resins, absence of animal-derived materials with TSE and BSE status, confirmation that no material of human origin is used, and batch traceability retained in the batch file. Cosmetic brands additionally ask for ISO 16128 natural-origin documentation, halal and kosher certification, vegan statements and allergen declarations, while manufacturing is expected to run under ISO 22716 cosmetic good manufacturing practice and an ISO 9001 quality system.

VI. Supply Chain Resilience and Export Logistics

Lyophilised tripeptide is a hygroscopic solid whose assigned peptide content drifts if vials are opened or stored in humid air, and whose related-substance profile can move if a cold chain fails. Because the molecule is highly polar and water-soluble, moisture control is the single most important logistics variable. Planning should assume sealed, desiccated packaging, controlled or refrigerated transit with documented excursion handling, and a validated frozen configuration for any solution or intermediate consignment.

6.1 Packaging Standards and Moisture/Contamination Control

• Container Closure and Desiccation: Amber glass or inert polymer containers with polytetrafluoroethylene-lined closures, sealed under nitrogen or argon where stability data support it, with desiccant and oxygen scavenger, moisture-barrier secondary packaging and a residual-moisture statement recorded on the certificate of analysis.
• Labelling and Documentation Set: Labels carrying CAS 175175-23-2, batch number, sequence, salt form, net peptide content, storage condition and the applicable Research Use Only or cosmetic-ingredient statement, supported by safety data sheet, certificate of analysis and tamper-evident sealing.

6.2 Dangerous Goods Identification and Transit Protocols

Dried tripeptide is normally shipped at ambient or refrigerated temperature in a validated insulated configuration, while solutions and intermediates move frozen with dry ice or phase-change materials under continuous temperature logging and defined excursion thresholds. Peptides themselves are generally not classified as dangerous goods, but accompanying solvents can change the classification, requiring UN-specification packaging, correct hazard labelling and a dangerous-goods declaration under IMDG, ADR or IATA rules, and misdeclaration of such consignments remains a frequent cause of detention. Air freight is preferred for speed and temperature stability.

VII. Enterprise Global Expansion Strategy Guide

For CDMOs and ingredient exporters seeking durable positions in short peptide supply, three priorities dominate: end-use segmentation, documentation depth and disciplined customer qualification.

1. Segment by Declared End Use: Operate distinct specification, documentation and quality-system streams for research-grade and cosmetic-grade material, so that ISO 22716 alignment, heavy-metal, endotoxin and bioburden limits and ISO 16128 or certification statements are applied only where the declared use requires them.
2. Sell Documentation and Never Claims: Provide identity, peptide content, related-substance, residual-solvent, water, heavy-metal and traceability data with methods validated along ICH Q2(R1) and Q14 principles, and refuse any request to supply efficacy claim language, leaving substantiation to the finished brand.
3. Qualify Customers and Control Change: Apply Know-Your-Customer screening and end-use declarations to every account, retain evidence of declined orders, and maintain advance notification of any resin, reagent or solvent change so that impurity-profile comparability can be reassessed under ICH Q7 and Q11 practice.

VIII. Conclusion

Glu-Asp-Arg is a small, hydrophilic tripeptide whose commercial difficulty is entirely a matter of specification and documentation. Synthesis is routine; what distinguishes a usable supply is whether the manufacturer controls and reports pyroglutamate and isoaspartate formation, assigns peptide content honestly, sets the counter-ion deliberately, and provides the impurity, heavy-metal and traceability data that both research and cosmetic customers are now required to hold on file.

The compliance boundary must be held firmly. This material has no approved therapeutic indication, research supply is Research Use Only and not for human or veterinary use, and no skin, anti-ageing or health claim is made or may be made on its behalf, with claim substantiation resting with the finished brand and its responsible person. Suppliers who internalise that boundary while delivering audit-ready documentation will be the ones qualified into brand and pharmaceutical supply chains as cosmetics and chemical regulation continues to tighten.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global L-Arginine, L-alpha-glutamyl-L-alpha-aspartyl- (Glu-Asp-Arg tripeptide) Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global L-Arginine, L-alpha-glutamyl-L-alpha-aspartyl- (Glu-Asp-Arg tripeptide) supply chain:

• China Peptide and Cosmetic Ingredient Manufacturing Base: Chinese producers combine short-peptide synthesis capacity with experience of NMPA cosmetic ingredient filing and the inventory of existing cosmetic ingredients in China, offering scale and cost advantage; buyers should verify ingredient listing position, heavy-metal data and documentation discipline.
• India GMP-Linked Peptide and Documentation Capability: Indian manufacturers bring cost-competitive synthesis alongside DMF and GMP experience from pharmaceutical work, making them useful partners where a tripeptide project may progress from research or cosmetic use into regulated supply.
• European Union Regulated Cosmetic and Reference-Grade Tier: EU producers operate under ISO 22716 cosmetic good manufacturing practice and ISO 9001, supply ISO 16128 documentation, halal, kosher and vegan certification where required, and provide audit-ready technical dossiers for responsible persons.